Somebody call Hasina

South Africa is executing a landmark shift in HIV prevention strategy with the nationwide rollout of lenacapavir (LEN), a twice-yearly injectable preventative designed to reduce HIV transmission among high-risk populations. The initiative represents a critical counterweight to deepening donor defunding pressures that have constrained South Africa's response to the continent's most severe HIV epidemic.

## What is lenacapavir and why does it matter for South Africa?

Lenacapavir is a long-acting monoclonal antibody administered via injection every six months, offering 96% efficacy in preventing HIV acquisition among uninfected individuals. Unlike daily oral PrEP (pre-exposure prophylaxis), the injection addresses adherence barriers that have limited uptake in resource-constrained settings. For South Africa—where an estimated 8.2 million people live with HIV—this represents a tangible tool to interrupt transmission chains beyond antiretroviral treatment alone.

The rollout spans 360 healthcare facilities nationwide, with clinical staff already trained and operational readiness confirmed. This decentralized deployment is strategically designed to reach communities in both urban centres and rural provinces where traditional oral prevention models have struggled with consistent uptake. The infrastructure investment signals government commitment to meet UNAIDS targets despite shrinking international aid.

## How does donor defunding shape this deployment?

South Africa's HIV programme has faced escalating financial pressure as global donors reallocate resources. The Global Fund, PEPFAR, and bilateral donors have signalled declining commitments, forcing the National Department of Health to accelerate innovation in high-impact, lower-cost interventions. Lenacapavir's twice-yearly schedule reduces clinical touchpoints compared to daily PrEP regimens, theoretically lowering system burden while maintaining prevention efficacy.

However, lenacapavir's unit cost (~$40 USD per injection globally) remains elevated for a middle-income country managing 11 million people on antiretroviral therapy. South Africa's negotiating power with manufacturers will determine whether local pricing reflects genuine affordability or remains a bottleneck to scaled access.

## What are the market and epidemiological implications?

The rollout creates a dual-track prevention ecosystem: oral PrEP for adherence-capable populations and injectable LEN for those with structural barriers to daily medication. This segmentation should theoretically optimize resource allocation. Early data from the 360-facility cohort will be critical; successful case studies could catalyse regional adoption across East and West Africa, where similar donor constraints and HIV burdens exist.

Pharmaceutical supply chains matter. Lenacapavir manufacturing capacity remains limited; South Africa's volume demands could stress global production. Conversations around local manufacturing or technology transfer to South African firms (Aspen, Cipla SA partnerships) will shape long-term sustainability.

The investment also signals epidemiological clarity: South Africa is concentrating prevention resources on transmission hotspots rather than universal coverage—a pragmatic triage during fiscal constraint. Key populations (sex workers, men who have sex with men, incarcerated persons) will likely be prioritized, though public health messaging will frame this as "equity-focused" rather than restrictive.